Intoleranţa ortostatică. Conceptul modern, clasificarea, manifestările clinice şi algoritmul de tratament

Selectează perioada

De la

Pîna la

2020

BAZINET, M., Replicor, Montreal, QC, Canada, PÂNTEA, V., dr.hab, PLĂCINTĂ, G., dr., MOSCALU, I., dr., CEBOTARESCU, V., dr., COJUHARI, L., dr., JIMBEI, P., IAROVOI, L., dr., SMESHNOI, V., dr., MUSTEAŢĂ, T., JUCOV, A., dr., DITTMER, U., Universitatea din Duisburg-Essen, Germania, KRAWCZYK, A., Universitatea din Duisburg-Essen, Germania, VAILLANT, A., Replicor, Montreal, QC, Canada Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology. 2020, nr. 8(158), 2194-2180. ISSN 0016-5085 ISSNe 1528-0012.

SANDBORN, W., University of California, San Diego, Statele Unite ale Americii, FERRANTE, M., Katholieke Universiteit Leuven, Belgia, BHANDARI, B., Delta Research Partners, Bastrop, SUA, Statele Unite ale Americii, BERLIBA, E., dr. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020, nr. 3(158), 549-537. ISSN 0016-5085 ISSNe 1528-0012.

3.	ZOULIM, F., Université Lyon, Franţa, LENZ, O., MOSCALU, I., dr. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020, nr. 2(159), 533-521. ISSN 0016-5085 ISSNe 1528-0012.

1-3 of 3